IPO Friday: Hypertension drugmaker Mineralys maps out $192M Nasdaq debut
Wall Street is welcoming a new drug developer to the stock markets for the second Friday in a row.
The biotech, nearing a Phase III for its lead asset, joins a small club of drug developers that has jumped onto the public markets recently after the IPO door appeared to slam shut last winter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.